MULTIPLE MYELOMA

Despite the small number of patients enrolled, the confirmatory phase 3 LIGHTHOUSE study of melphalan flufenamide in patients with relapsed/refractory multiple myeloma demonstrates promising safety and efficacy.

Based on positive responses from the phase 1/2 MajesTEC-1 trial, the FDA has granted approval for the use of teclistamab-cqyv in relapsed or refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Jeffrey Zonder, MD, discussed with participants the later-line therapy options for patients who have relapsed following several lines of treatment for multiple myeloma.

Adam Cohen, MD, discusses when patients should receive chimeric antigen receptor T-cell therapies for relapsed/refractory multiple myeloma.

At a 2022 NCCN meeting, a panel discussed the use of immunotherapy for the treatment of patients with multiple myeloma, specifically how to choose the best course of action and how to manage toxicities.

Peter Voorhees, MD, discussed managing adverse events related to belantamab mafadotin in patients with relapsed/refractory multiple myeloma during a live event.

Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.

During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.

Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.

The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.

Interim findings from the DREAMM-6 study hint that belantamab mafodotin plus lenalidomide and dexamethasone is effective with tolerable safety in patients with relapsed or refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Saad Z. Usmani, MD, MBC, discussed the case of a patient who progressed on first- and second-line therapy for multiple myeloma and did not receive a stem cell transplant.

With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.

During 10th Annual Meeting of the Society of Hematologic Oncology, Ajay Nooka, MD, discussed the new regimens with positive clinical trials in RRMM.

Decision-making for the second to fourth lines of therapy in multiple myeloma can depend on many factors, and clinicians still face unanswered questions, according to Krina K. Patel, MD, MSc.

In an interview with Targeted Oncology, Paul Richardson, MD, discussed the outcome of the ODAC meeting and provided his personal insights on what may be next for melphalan flufenamide.

Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Cristina Gasparetto, MD, discussed data supporting the use of selinxor for patients with relapsed/refractory multiple myeloma.

Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.

The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities

During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.

The CoMMpass genomic data set of patients with multiple myeloma was utilized by investigators, contributing to 19 abstracts reported at the International Myeloma Society.

The phase 2 CARTITUDE study showed encouraging response in the heavily-pretreated multiple myeloma population. Now, the phase 3 CARTITUDE-4 trial is underway.

An association between biallelic deletion of TNFRSF17 and resistance to therapies like chimeric antigen receptor T cells and T-cell engagers has been identified in myeloma.

The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.